cat no | io1028
ioOligodendrocyte-like cells
Human iPSC-derived oligodendrocyte-like cells
ioOligodendrocyte-like cells are highly characterised cells that resemble a pre-myelinating oligodendrocyte state. These cells enable the screening of compounds that modulate myelination, supporting drug development for neurodegenerative and demyelinating diseases, such as multiple sclerosis.
Place your order
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
Benchtop benefits
Defined
Human O4+ cells initially display a typical OPC-like morphology. They mature into oligodendrocyte-like cells that have multiple branched processes.
Quick
O4+ cells are ready from day 1 post-revival and rapidly mature into O4+ MBP+ oligodendrocyte-like cells with an 8 day protocol.
Easy to use
Cryopreserved cells arrive ready to be used upon revival. Simple monolayer culture protocol. No lentiviral transduction required.
Ready within days
The opti-ox powered cells rapidly mature, transitioning into an oligodendrocyte-like morphology within 8 days
Time-lapse video capturing the rapid and homogeneous acquisition of an OPC-like morphology and maturation towards an oligodendrocyte-like morphology with multiple branched processes, upon thawing of cryopreserved cells. 8 day time course; scale bar: 500 μm.
Cells enable the generation of experimental readouts within 8 days post-revival
Highly characterised and defined
ioOligodendrocyte-like cells express oligodendroglial-specific markers
Immunofluorescent staining of the cells at day 1 (upper panel) and day 8 (lower panel) post-revival. At day 1, the cells are positive for the oligodendrocyte-specific marker O4 (red), and the DAPI counterstain (blue). At day 8, ioOligodendrocyte-like cells show an increased complexity and are positive for O4 (red), the myelin basic protein (MBP) (green), and the DAPI counterstain (blue). 100X magnification; scale bar: 100 μm.
View the step-by-step immunofluorescent staining protocol used to generate this data.
Cells show an oligodendrocyte-like morphology by day 8
Upon deterministic programming, cells show rapid morphological changes, acquiring an OPC-like morphology by day 1 post-revival. By day 8, cells have matured and display an oligodendrocyte-like morphology. Brightfield images show day 1 and day 8 post-thawing; scale bar: 400 μm.
Key oligodendroglial genes are expressed by ioOligodendrocyte-like cells
Following deterministic programming, the cells downregulate expression of the pluripotency gene OCT4, whilst demonstrating robust expression of relevant oligodendroglial markers, including PDGFRA, PLP1, MBP, CNP, MAG, and MYRF. Gene expression levels assessed by RT-qPCR, data expressed relative to the reference (housekeeping) gene, HMBS. Data represents day 1 and day 8 post-revival samples; n=2 technical replicates.
Lot-to-lot consistency
.png?width=1715&height=396&name=ioOligodendrocyte-PCA_AllSamples2%20(1).png)
Bulk RNA-sequencing analysis was performed on three different lots of manufactured product at day 1 and day 8 post revival. Principal component analysis (PCA) represents the variance in gene expression between the three different lots of ioOligodendrocyte-like cells. This analysis shows lots clustering very closely which demonstrates high consistency at each given timepoint. This lot-to-lot consistency in every vial gives scientists confidence in their experimental reproducibility. Colours represent the parental non-induced hiPSC cell line and the three lots of ioOligodendrocyte-like cells; shapes represent different timepoints.
Expression levels for specific genes of interest can be requested by contacting our team at technical@bit.bio.
Cells arrive ready to plate
ioOligodendrocyte-like cells are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Induction which is carried out at bit.bio, Stabilisation for 1 day (Phase 1), and Maturation from day 1 to day 8 (Phase 2). Phases 1 and 2 after revival of cells are carried out by the customer.
Hoescht(blue)_day12v2.png?width=604&name=bit.bio_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png)
.png?width=604&name=Tech%20Nets%20online%20symposium%20header%20(1).png)
Differentiating iPSCs - which approach works best?
Download this infographic to find out how the approach used to generate human iPSC-derived cells influences purity, batch consistency and protocol speed.
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells